Funding news
Synply logo

Synply Secures $5.5 Million in Seed Round Funding to Revolutionize Loan Syndication for Banks

Recently funded · $5.5M SeedFinancial Services

Get the full Synply company profile

Access contacts, investors, buying signals & more

Open in Dashboard

We are excited to announce that Synply, the innovative cloud-based technology company revolutionizing the loan syndication process for banks, has successfully raised $5,500,000 in its latest funding round. Founded and incubated within the esteemed Live Oak Bank, Synply is dedicated to creating a more streamlined and efficient platform that alleviates the pain points of traditional loan syndication. With an expert team composed of seasoned bankers, Synply recognizes the challenges that financial institutions face and has developed a solution designed specifically to meet those needs. “We built Synply because we saw a critical need for a modern and intuitive platform specifically designed for the loan syndication process,” stated Corbin Penland, CEO of Synply. The funds raised will be allocated towards enhancing the platform's features, expanding the engineering team, and increasing market outreach to ensure that more banks can benefit from Synply’s end-to-end efficiency. The platform allows institutions to manage the complete loan syndication lifecycle—from origination to servicing—within a single, user-friendly interface. Additionally, Synply’s system-agnostic design ensures compatibility with existing banking systems, cutting down on integration complexities. With a vision to empower banks to prioritize relationship-building and portfolio management rather than being bogged down by cumbersome processes, Synply is poised to become a game-changer in the industry. This funding marks a significant milestone in our journey as we continue to enhance the future of loan syndication for banks worldwide.

Other recently funded companies

View all

Other recent Seed rounds

Companies that recently closed a Seed round.

#CompanyAmount
1
Riverlution logo

Riverlution

United Kingdom

$40.4K
2
Goldenrod Therapeutics logo

Goldenrod Therapeutics

United States

$6.5M
3
HAGA.BIO logo

HAGA.BIO

Sweden

$2.3M
4
Hexigone Inhibitors logo

Hexigone Inhibitors

United Kingdom

$1.5M
5
Edify Systems logo

Edify Systems

United Kingdom

$4.0M